Physician profile
Celeste Stevens
NPI 1346882305
$2,638.43
in general payments reported to CMS, 2019-2025
28 companies · $689 in 2025
The $689 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $419 · 2023: $663 · 2024: $868 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $465.45 | 2022-2025 | |
| Amgen INC. | $376.00 | 2022-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $272.85 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $264.06 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $179.66 | 2023-2025 | Wainua, Farxiga, Andexxa |
| Novo Nordisk INC | $138.27 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $99.90 | 2023-2025 | |
| Pfizer INC. | $95.03 | 2023-2025 | |
| Boston Scientific Corporation | $92.63 | 2023-2025 | Watchman Flx, General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.77 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $73.54 | 2022-2023 | |
| Scpharmaceuticals INC. | $51.91 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $47.81 | 2025 | Dupixent |
| Tactile Systems Technology INC | $45.71 | 2023 | Flexitouch Plus, Entre Plus |
| Kiniksa Pharmaceuticals International, Plc | $45.26 | 2024 | Arcalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $44.68 | 2024 | Barostim Neo System |
| Glaxosmithkline, LLC. | $41.05 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $32.16 | 2024-2025 | |
| Esperion Therapeutics, INC. | $26.78 | 2025 | Nexletol |
| Baxter Healthcare | $24.75 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $20.63 | 2024 | Camzyos |
| Edwards Lifesciences Corporation | $19.59 | 2024 | Sapien 3 Ultra Resilia |
| Ionis Pharmaceuticals, INC. | $18.52 | 2025 | Dawnzera |
| Bridgebio Pharma, INC. | $18.10 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $17.51 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.15 | 2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $17.04 | 2024 | Uptravi, Opsumit |
| Lilly USA, LLC | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.